Revvity

Revvity's moat score of 33/100 is notably low for a healthcare equipment company, suggesting limited sustainable competitive advantages. This score largely reflects the profound strategic transformation the company has undergone, specifically the significant divestiture of its Applied, Food, and Enterprise Services (AFES) business.

While the remaining diagnostics and life sciences segments may possess proprietary technologies or intellectual property, the market perceives this restructuring as having diluted or redefined the company's traditional competitive barriers.

The negative 3-year Revenue CAGR of -17.4% strongly indicates this portfolio shrinkage and introduces uncertainty regarding the long-term durability of the new, more focused entity's competitive positioning.

Without stronger barriers to entry, switching costs, or network effects, Revvity may face ongoing pressure from established rivals and new entrants in its core markets.

The exceptionally low pricing power score of 8/100 for Revvity is a significant concern, especially within the healthcare equipment industry where specialized products can sometimes command premiums.

This indicates the company operates in highly competitive segments or offers products that are susceptible to commoditization and intense customer negotiation. Despite a TTM Operating Margin of 11.5% and TTM Net Margin of 7.4%, these margins are likely achieved through cost management rather than robust pricing leverage.

The divestiture of the AFES business might have also removed higher-margin, less price-sensitive product lines, leaving a portfolio with greater exposure to pricing pressures.

Sustaining or growing profitability will prove challenging if the company cannot differentiate its offerings sufficiently to justify higher prices or maintain favorable terms with large institutional buyers and healthcare systems.

Revvity's predictability score of 60/100 is moderate, reflecting a company in a state of flux rather than stable, consistent operations. The significant strategic divestiture, which largely explains the -17.4% 3-year Revenue CAGR, introduces substantial uncertainty about future revenue trajectories and earnings stability.

While the healthcare sector generally benefits from somewhat resilient demand, Revvity's recent corporate actions make historical trends less indicative of future performance. The healthy TTM Free Cash Flow Margin of 17.5% does provide some measure of operational stability.

However, the dramatic 5-year Net Income CAGR of 48.3% suggests that earnings have been subject to considerable swings, possibly due to one-off events or the divestiture itself, rather than predictable organic growth. Investors will require clearer guidance on the go-forward business model's intrinsic stability.

Revvity demonstrates robust financial strength, earning an impressive score of 80/100. This is a significant positive amidst other challenges. The company maintains a very conservative Debt to Equity ratio of 0.36x, indicating minimal leverage and a strong equity base that provides a substantial buffer against economic downturns.

Its Current Ratio of 1.75x signals ample short-term liquidity, ensuring the company can comfortably meet its immediate obligations. Furthermore, Revvity exhibits strong cash generation capabilities, with TTM Free Cash Flow of $1.08 billion and a healthy TTM FCF Margin of 17.5%.

This excellent cash flow provides operational flexibility, supports potential strategic investments, and offers resilience as the company navigates its post-divestiture phase. The strong balance sheet is a critical foundation for future growth and stability.

Revvity's capital allocation score of 46/100 suggests concerns about the effectiveness of management's investment decisions. The low TTM Return on Equity of 6.2% indicates that the company is not currently generating strong profits relative to the equity invested by shareholders.

While the recent strategic divestiture was a major capital allocation decision to reshape the company, the subsequent returns on the remaining assets are still being evaluated.

There may be questions about how the proceeds from this divestiture are being redeployed and whether investments in R&D, M&A, or organic growth initiatives within the new Revvity are yielding sufficient shareholder value.

The company needs to demonstrate improved capital efficiency and a clearer path to higher returns on invested capital to improve this score.

Revvity's management receives a score of 53/100, indicating an acceptable but not outstanding performance. The management team has successfully navigated the complex and challenging divestiture of its Applied, Food, and Enterprise Services business and the subsequent rebranding.

This strategic overhaul, which is reflected in the -17.4% 3-year Revenue CAGR, demonstrates a clear vision to refocus the company on its core diagnostics and life sciences segments.

However, the relatively low TTM Return on Equity of 6.2% and the concerns surrounding capital allocation, evidenced by a score of 46/100, suggest that while management executed a major strategic shift, they still need to prove their ability to consistently translate this new focus into superior financial performance and shareholder returns for the revitalized Revvity.

The market is likely observing how effectively the new strategy drives future growth and profitability.